NDAORALCAPSULEPriority Review
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TURALIO (pexidartinib hydrochloride) is an oral small-molecule receptor tyrosine kinase inhibitor approved for tenosynovial giant cell tumor (TGCT), a rare soft-tissue neoplasm. The drug targets colony-stimulating factor 1 receptor (CSF1R) to inhibit proliferation of pathogenic macrophages and fibroblastic cells in the tumor microenvironment.
$0.002BPart D
Peak11.7 years to LOEProduct is in peak commercial phase with early adoption signals; modest Part D spending reflects orphan disease patient base and specialized market penetration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment
Started Jan 2021
30 enrolled
HepatotoxicityTenosynovial Giant Cell Tumor
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
Started Oct 2020
32 enrolled
Tenosynovial Giant Cell Tumor
Career Relevance
Working on TURALIO offers exposure to orphan disease commercialization, a specialized discipline requiring deep payer navigation and physician relationship-building in niche markets. The stable lifecycle and robust patent position provide career continuity, though limited market size restricts team headcount and growth trajectory compared to primary-care or oncology franchises.
Worked on TURALIO at Daiichi Sankyo? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.